Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Fredun Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹2,400.51Fairly Valued by 6.69%vs CMP ₹2,250.00

P/E (37.3) × ROE (15.8%) × BV (₹509.00) × DY (0.03%)

₹1,355.50Overvalued by 39.76%vs CMP ₹2,250.00
MoS: -66% (Negative)Confidence: 63/100 (Moderate)Models: 1 Under, 8 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹3,292.8424%Under (+46.3%)
Graham NumberEarnings₹891.8417%Over (-60.4%)
DCFCash Flow₹1,110.7911%Over (-50.6%)
Net Asset ValueAssets₹504.448%Over (-77.6%)
EV/EBITDAEnterprise₹881.8510%Over (-60.8%)
Dividend DiscountDividends₹38.5010%Over (-98.3%)
Earnings YieldEarnings₹694.508%Over (-69.1%)
ROCE CapitalReturns₹858.118%Over (-61.9%)
Revenue MultipleRevenue₹827.426%Over (-63.2%)
Consensus (9 models)₹1,355.50100%Overvalued
Key Drivers: EPS CAGR 37.2% lifts DCF — verify sustainability. | Wide model spread (₹39–₹3,293) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 37.2%

*Investments are subject to market risks

Analyst Summary

Fredun Pharmaceuticals Ltd operates in the Pharmaceuticals segment, NSE: FREDUN | BSE: 539730, current market price is ₹2,250.00, market cap is 1,240 Cr.. At a glance, stock P/E is 37.3, ROE is 15.8 %, ROCE is 21.5 %, book value is 509, dividend yield is 0.03 %. The latest intrinsic value estimate is ₹1,355.50, around 39.8% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹456 Cr versus the prior period change of 31.0%, while latest net profit is about ₹21 Cr with a prior-period change of 31.3%. The 52-week range shown on this page is 2,620/786, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisFredun Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 08/06/1987 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CI…

This summary is generated from the stock page data available for Fredun Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

74
Fredun Pharmaceuticals Ltd scores 74/100 (Strong)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health75/100 · Strong
ROCE 21.5% ExcellentROE 15.8% GoodD/E 0.92 ModerateInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money85/100 · Strong
FII holding up 1.06% (6mo) AccumulatingDII holding up 1.30% MF buyingPromoter holding at 43.1% Stable
Earnings Quality65/100 · Strong
OPM expanding (8% → 12%) Improving
Quarterly Momentum90/100 · Strong
Revenue (4Q): +46% YoY AcceleratingProfit (4Q): +89% YoY Strong
Industry Rank60/100 · Moderate
P/E 37.3 vs industry 49.9 In-lineROCE 21.5% vs industry 24.9% Average3Y sales CAGR: 27% High growth

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily.

Share Price and Basic Stock Data

Last Updated: June 12, 2026, 8:28 am

Market Cap 1,240 Cr.
Current Price 2,250
Intrinsic Value₹1,355.50
High / Low 2,620/786
Stock P/E37.3
Book Value 509
Dividend Yield0.03 %
ROCE21.5 %
ROE15.8 %
Face Value 10.0
PEG Ratio1.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Fredun Pharmaceuticals Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Fredun Pharmaceuticals Ltd 1,240 Cr. 2,250 2,620/78637.3 5090.03 %21.5 %15.8 % 10.0
TTK Healthcare Ltd 1,257 Cr. 890 1,402/73518.2 7891.12 %8.04 %6.32 % 10.0
Lincoln Pharmaceuticals Ltd 1,261 Cr. 630 770/44014.4 3780.29 %16.3 %12.3 % 10.0
Syncom Formulations (India) Ltd 1,308 Cr. 13.9 21.9/10.217.2 4.390.00 %26.8 %20.2 % 1.00
Ind-Swift Laboratories Ltd 1,379 Cr. 159 174/87.027.9 1590.00 %4.70 %3.87 % 10.0
Industry Average21,214.12 Cr1,194.5949.88218.190.36%24.92%18.30%6.10

All Competitor Stocks of Fredun Pharmaceuticals Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 788062828711879107103167120145161
Expenses 7168547276107689389150103123135
Operating Profit 712810111110141317172226
OPM % 9%15%12%12%12%9%13%13%13%10%14%15%16%
Other Income 0000000000000
Interest 24334445587811
Depreciation 1111111111122
Profit before tax 584666687891314
Tax % 25%51%41%32%27%13%25%44%25%12%25%25%25%
Net Profit 342445445771010
EPS in Rs 7.668.585.248.418.9810.768.759.0411.2914.9714.3420.6119.53

Last Updated: March 3, 2026, 9:48 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 27, 2026, 5:20 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 212542576097113134222275348456593
Expenses 202438535487104126208247310401510
Operating Profit 1243610881428385583
OPM % 7%7%9%6%10%11%7%6%6%10%11%12%14%
Other Income 0012001122100
Interest 1122234459142233
Depreciation 1111112223446
Profit before tax 01223623918212844
Tax % 47%52%42%36%34%28%24%37%26%38%27%26%
Net Profit 00112422611162134
EPS in Rs 1.021.114.556.085.1111.184.765.0414.3023.8533.2244.0769.45
Dividend Payout % 0%0%13%10%12%6%14%14%5%3%2%2%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)0.00%100.00%100.00%-50.00%0.00%200.00%83.33%45.45%31.25%
Change in YoY Net Profit Growth (%)0.00%100.00%0.00%-150.00%50.00%200.00%-116.67%-37.88%-14.20%

Fredun Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:34%
5 Years:32%
3 Years:27%
TTM:36%
Compounded Profit Growth
10 Years:54%
5 Years:61%
3 Years:49%
TTM:35%
Stock Price CAGR
10 Years:%
5 Years:41%
3 Years:4%
1 Year:64%
Return on Equity
10 Years:13%
5 Years:13%
3 Years:15%
Last Year:16%

Last Updated: September 5, 2025, 3:30 pm

Balance Sheet

Last Updated: June 4, 2026, 2:00 am

MonthMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital 222344445555
Reserves 012193537396492117137273
Borrowings 91621101935405387106166222
Other Liabilities 11243047476579667481179141
Total Liabilities 23435679105141162187257308487642
Fixed Assets 815161631313032394753118
CWIP 1041100000000
Investments 000000000122
Other Assets 1429365274110131155218260433522
Total Assets 23435679105141162187257308487642

Reserves and Borrowings Chart

Cash Flow

MonthMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity + 234171-110-2-14-0-2116
Cash from Investing Activity + -3-6-7-8-5-1-1-4-9-8-6-74
Cash from Financing Activity + 133-8414-1725626122
Net Cash Flow 01-1102-211-2-165
Free Cash Flow -1-3-39-4-12-1-7-24-8-27-57
CFO/OP 108%85%117%303%8%-128%2%-17%-52%-1%-43%18%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow1.00-7.00-12.00-18.00-4.00-9.00-27.00-32.00-39.00-59.00-68.00-111.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 59759813194671261121484668142
Inventory Days 1071021406817024922724296264246265
Days Payable 15216722122436020520821510110488160
Cash Conversion Cycle 141117-24-96110145139144205225247
Working Capital Days -44-54-44-39426665116126979276
ROCE %14%14%25%18%16%21%10%10%13%18%17%19%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Feb 2026
Promoters 49.62%49.31%49.16%49.17%49.17%48.93%48.93%48.93%48.93%48.93%43.06%43.06%
FIIs 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.01%0.46%1.06%
DIIs 1.64%1.60%1.60%1.60%1.60%1.59%1.59%1.59%1.59%1.61%3.48%2.89%
Public 48.74%49.08%49.24%49.24%49.23%49.47%49.47%49.47%49.49%49.46%53.00%52.99%
No. of Shareholders 4,6256,3136,8377,5077,5118,0188,1217,9767,9068,1208,7658,443

Shareholding Pattern Chart

No. of Shareholders

Fredun Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 44.8333.6624.1311.285.05
Diluted EPS (Rs.) 44.8333.3222.9311.285.05
Cash EPS (Rs.) 53.4941.3230.0419.1610.07
Book Value[Excl.RevalReserv]/Share (Rs.) 299.47258.49212.64153.54107.96
Book Value[Incl.RevalReserv]/Share (Rs.) 299.47258.49212.64153.54107.96
Dividend / Share (Rs.) 0.700.700.700.700.70
Revenue From Operations / Share (Rs.) 961.13740.88606.04506.38335.60
PBDIT / Share (Rs.) 116.6982.7865.3134.8026.41
PBIT / Share (Rs.) 107.2774.7059.1129.9321.39
PBT / Share (Rs.) 59.8745.6538.6319.408.04
Net Profit / Share (Rs.) 44.0733.2523.8414.295.05
PBDIT Margin (%) 12.1411.1710.776.877.86
PBIT Margin (%) 11.1610.089.755.916.37
PBT Margin (%) 6.226.166.373.832.39
Net Profit Margin (%) 4.584.483.932.821.50
Return on Networth / Equity (%) 14.7112.8611.219.304.67
Return on Capital Employeed (%) 31.7824.9317.7211.7111.35
Return On Assets (%) 4.275.074.203.381.24
Long Term Debt / Equity (X) 0.060.100.500.610.67
Total Debt / Equity (X) 1.180.860.890.770.92
Asset Turnover Ratio (%) 1.141.231.241.290.90
Current Ratio (X) 1.311.542.042.071.50
Quick Ratio (X) 0.570.490.621.440.72
Inventory Turnover Ratio (X) 2.191.752.513.111.71
Dividend Payout Ratio (NP) (%) 1.582.092.884.8913.30
Dividend Payout Ratio (CP) (%) 1.301.682.283.656.67
Earning Retention Ratio (%) 98.4297.9197.1295.1186.70
Cash Earning Retention Ratio (%) 98.7098.3297.7296.3593.33
Interest Coverage Ratio (X) 2.462.853.193.302.53
Interest Coverage Ratio (Post Tax) (X) 1.932.142.162.361.76
Enterprise Value (Cr.) 477.16441.23435.36456.41223.45
EV / Net Operating Revenue (X) 1.051.271.592.031.67
EV / EBITDA (X) 8.6611.3414.7129.5921.21
MarketCap / Net Operating Revenue (X) 0.690.961.281.811.38
Retention Ratios (%) 98.4197.9097.1195.1086.69
Price / BV (X) 2.232.773.665.964.29
Price / Net Operating Revenue (X) 0.690.961.281.811.38
EarningsYield 0.060.040.030.010.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Fredun Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 08/06/1987 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24239MH1987PLC043662 and registration number is 043662. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 635.47 Cr. and Equity Capital is Rs. 5.47 Cr. for the Year ended 31/03/2026.
INDUSTRYADDRESSCONTACT
PharmaceuticalsURMI ESTATE, Mumbai Maharashtra 400013Contact not found
Management
NamePosition Held
Dr.(Mrs.) Daulat N MedhoraChairman & Jt. M. D
Mr. Fredun MedhoraManaging Director & CFO
Mrs. Daisy D�souzaInd. Non-Executive Director
Mr. Anshu AgarwalInd. Non-Executive Director
Mrs. Sonal DesaiInd. Non-Executive Director
Ms. Pooja Narendra SanghaviInd. Non-Executive Director

FAQ

What is the intrinsic value of Fredun Pharmaceuticals Ltd and is it undervalued?

As of 20 June 2026, Fredun Pharmaceuticals Ltd's intrinsic value is ₹1355.50, which is 39.76% lower than the current market price of ₹2,250.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (15.8 %), book value (₹509), dividend yield (0.03 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Fredun Pharmaceuticals Ltd?

Fredun Pharmaceuticals Ltd is trading at ₹2,250.00 as of 20 June 2026, with a FY2026-2027 high of ₹2,620 and low of ₹786. The stock is currently near its 52-week high. Market cap stands at ₹1,240 Cr..

How does Fredun Pharmaceuticals Ltd's P/E ratio compare to its industry?

Fredun Pharmaceuticals Ltd has a P/E ratio of 37.3, which is below the industry average of 49.88. This is broadly in line with or below the industry average.

Is Fredun Pharmaceuticals Ltd financially healthy?

Key indicators for Fredun Pharmaceuticals Ltd: ROCE of 21.5 % indicates efficient capital utilization; ROE of 15.8 % shows strong shareholder returns. Dividend yield is 0.03 %.

Is Fredun Pharmaceuticals Ltd profitable and how is the profit trend?

Fredun Pharmaceuticals Ltd reported a net profit of ₹21 Cr in Mar 2025 on revenue of ₹456 Cr. Compared to ₹6 Cr in Mar 2022, the net profit shows an improving trend.

Does Fredun Pharmaceuticals Ltd pay dividends?

Fredun Pharmaceuticals Ltd has a dividend yield of 0.03 % at the current price of ₹2,250.00. The company pays dividends, though the yield is modest.

Last Updated: June 12, 2026, 8:28 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 539730 | NSE: FREDUN
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Fredun Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports